Guidance for good health economic modelling practices in personalised medicines
This guideline helps researchers and decision-makers improve the quality and consistency of economic evaluations for personalised medicines. It offers practical advice on how to model the value of these treatments, especially when evidence is limited or uncertain.
At a glance
Use when
Developing or reviewing economic models for personalised medicine, especially in contexts with limited or uncertain evidence
Avoid when
When evaluating non-personalised, broad-population treatments where standard economic evaluation methods suffice
Inputs
Clinical and economic data, test-treatment pathways, evidence on compliance, survival data (including immature data), information on managed entry agreements
Outputs
Structured and transparent economic models for personalised medicine with improved methodological consistency and reporting quality
How it works
Developed through a targeted literature review, expert interviews, and a systematic review of economic evaluations, this guidance provides 23 recommendations to address methodological challenges in modelling personalised medicine. Key areas include test-treatment pathway modelling, use of non-randomised data, parameterisation of structural uncertainty, perspective, discounting, handling of premature survival data, inclusion of additional value elements, compliance, and managed entry agreements.
- Project
- HEcoPerMed
- Funding
- Horizon 2020
- Project status
- Completed 2022
- HTA domains
- Costs & Economic Evaluation
- Categories
- Cost-effectiveness Modelling
- Technology
- Medicines
- Assumptions
- That current economic modelling practices for personalised medicine are inconsistent and often fail to address key methodological challenges; that improved guidance can enhance model reliability and policy relevance
- Strengths
- Developed through a robust process including literature reviews, expert input, and stakeholder feedback; addresses both methodological and practical challenges; promotes transparency and consistency in modelling
- Limitations
- Does not resolve all underlying uncertainties in personalised medicine data; implementation depends on data availability and local regulatory contexts
- Also known as
- HEcoPerMed Guidance, Guidance for good health economic modelling practices in personalised medicines
Questions this answers
- › How should I model the cost-effectiveness of a personalised medicine?
- › What data sources are acceptable when randomised trials are not available?
- › How should uncertainty be handled in models of personalised medicine?
- › What additional benefits of personalised medicine should be considered?
- › How do patient and clinician compliance affect model outcomes?
- › When and how should managed entry agreements be included in economic models?
Related methods
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.